Adaptive Brain Stimulation Arrives in India as a Cheaper Rival Looms

On 23 April 2026, Medtronic launched its Adaptive Deep Brain Stimulation (aDBS) system in India, built on its FDA-cleared BrainSense technology and recognised as a 2025 TIME Best Invention. The clinical need is large: India carries roughly 10% of the global Parkinson's disease burden and is projected to have the second-highest national caseload within about five years. But the more consequential Indian story is not the import. It is the indigenous device taking shape in a government lab, and what it could do to the price of treatment.

What adaptive stimulation does

Deep brain stimulation treats Parkinson's, dystonia and severe tremor by implanting thin electrodes deep in the brain and a pulse generator under the skin of the chest, delivering electrical pulses that quiet the abnormal signalling behind the symptoms. It is one of modern neurology's genuine successes, capable of restoring years of function to people whose medication has stopped working. But conventional DBS is open-loop: it delivers a more or less constant stimulation, tuned by a clinician during occasional visits, regardless of the patient's moment-to-moment state.

Adaptive DBS closes that loop. The device senses the brain's own electrical activity, specifically the local field potentials associated with symptoms, and adjusts stimulation in response, dialling it up when symptoms emerge and down when they subside. The benefits can include better symptom control, fewer side effects from over-stimulation, and longer battery life, which matters because a depleted pulse generator means another surgery. It is a real advance, and having it available in India is good for patients who can reach it.

The affordability fault line

The catch is cost, and it is where the Indian story turns. DBS in India runs to roughly $22,000 to $30,000, and at a leading public centre like the Sree Chitra Tirunal Institute the surgery has cost on the order of ₹16 lakh. An expert consensus from the Parkinson's Research Alliance India, published in the Journal of Neural Transmission in 2026, identifies cost and low awareness as the central reasons DBS remains badly underused in a country with such a high disease burden. An even more sophisticated imported system does not, by itself, fix an access problem rooted in price; if anything, the most advanced devices sit at the top of the cost range.

This is the fault line running through Indian neurotechnology: the gap between what is technically available and what is actually affordable to the people who need it.

AnuChitra: the indigenous bet

Which is why AnuChitra is the strategically important development. The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), through its Division of Medical Instrumentation and in partnership with the Bhabha Atomic Research Centre (BARC), has developed what is described as India's first indigenous deep brain stimulator, for Parkinson's and dystonia. The project began in 2016 under then-director Dr. Asha Kishore, with support from the DST's Technical Research Centre, and it has now been transferred, on a non-exclusive basis, to the Indore-based manufacturer Shree Pacetronix.

The numbers are the headline. SCTIMST's internal valuation for the device is around ₹1.5 lakh, and the expected market price is under ₹5 lakh, against the roughly ₹16 lakh of current treatment, a reduction on the order of 70%. If those figures hold through trials and into production, they would change who can plausibly be offered DBS in India, moving it from a therapy rationed by wealth toward something a public health system could realistically scale.

A widening ecosystem, and the caveats

AnuChitra does not stand alone. India's clinical-neurotech base has been thickening: AIIMS Delhi hosted the country's first dedicated DBS workshop for movement disorders in December 2025, became the first government hospital to deploy incision-free MR-guided focused ultrasound for neurological conditions, and has pioneered a robotic technique for drug-resistant epilepsy. The capability being built is broad, not a single device, which is what an ecosystem rather than a one-off looks like.

The honest caveats matter. AnuChitra is at the pre-trial and technology-transfer stage, with clinical trials and full-scale production still years away, and the roughly 70% saving is a projection rather than a delivered price. Today, the imported adaptive system is unambiguously the more advanced technology. But the contest this sets up, imported sophistication versus indigenous affordability, is the defining tension of Indian neurotech, and in a high-burden, deeply price-sensitive market, affordability is very often what decides how widely a therapy actually reaches the patients who need it. A cheaper device that thousands can receive may do more total good than a superior one that only hundreds can afford.